Hims & Hers Health, Inc. (HIMS) News
Track canonical SquawkNews coverage tagged to HIMS, Hims & Hers Health, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 49 indexed stories across 18 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
FDA warns of severe risks from misbranded GLP-1 weight-loss drugs
The FDA warned patients and providers about severe health risks from unapproved and compounded GLP-1 weight-loss drugs, including illegally marketed semaglutide and tirzepatide. Hims & Hers stock closed 3.85% lower Tuesd
REGULATION | Sep 02, 2026, 11:40 AM UTC
L
HIMS falls after FDA GLP-1 drug warning overshadows Australia expansion
Hims & Hers Health shares began September in the red as an FDA warning about unapproved GLP-1 weight-loss drugs drew focus. The stock fell 4% to close at $28.44 on Tuesday.
REGULATION | Sep 02, 2026, 04:37 AM UTC
L
HIMS enters Australia, marking first Asia-Pacific expansion
Hims is entering Australia, marking its first expansion into the Asia-Pacific market.
EQUITY | Aug 31, 2026, 07:07 PM UTC
L
Hims & Hers Health enters Australia, first Asia-Pacific market
Hims & Hers Health enters Australia, marking its first Asia-Pacific market presence.
EQUITY | Aug 31, 2026, 07:04 PM UTC
L
Hims expands into Australia with personalised men’s care
Hims says it has arrived in Australia with personalised care for men nationwide.
EQUITY | Aug 31, 2026, 07:00 PM UTC
L
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
EQUITY | Aug 31, 2026, 06:55 PM UTC
M
Hims placed on Visa monitoring over weight-loss subscription disputes
Hims & Hers Health was put on notice by Visa for excessive customer complaints in its weight-loss subscription business and entered Visa’s Acquirer Monitoring Program after a surge of July credit card disputes.
REGULATION | Aug 24, 2026, 01:51 PM UTC
L
Barclays cuts Hims & Hers price target to $35, keeps Overweight
Barclays lowers its price target on Hims & Hers Health to $35 from $39 and keeps an Overweight rating.
EQUITY | Aug 20, 2026, 01:19 PM UTC
L
HIMS - Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
HIMS - Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
EQUITY | Aug 18, 2026, 11:55 PM UTC
L
Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33
Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE: HIMS ) with a Neutral and lowers the price target from $35 to $33.
EQUITY | Aug 11, 2026, 07:32 PM UTC
L
Why Is Hims & Hers Health Stock Falling Tuesday?
Hims & Hers Health Inc. (NYSE: HIMS ) stock fell Tuesday after the company reported mixed second-quarter results following Monday's closing bell. Nasdaq futures rose 0.28%, while S&P 500 futures gained 0.16%. Concerns ov
EARNINGS | Aug 11, 2026, 01:16 PM UTC
L
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of OppFi Inc (NYSE: OPFI ) fell sharply in pre-market trading after the company reported worse-than-expected
EARNINGS | Aug 11, 2026, 12:04 PM UTC
L
Rocket Lab USA, Hims & Hers, AST SpaceMobile, Archer Aviation and Plug Power: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.11% to 53,975.98, the S&P 500 declining 0.06% to 7,753.11 and the Nasdaq slipping 0.32% to 26,605.35 These are the top stocks tha
EARNINGS | Aug 11, 2026, 01:37 AM UTC
L
Hims & Hers Guides Q3 Revenue To $880M-$900M
Hims & Hers raises FY revenue outlook to $3.10B-$3.30B
EARNINGS | Aug 10, 2026, 08:13 PM UTC
L
Hims & Hers Health Raises FY2026 Sales Guidance from $2.800B-$3.000B to $3.100B-$3.300B vs $2.928B Est
Hims & Hers Health (NYSE: HIMS ) raises FY2026 sales outlook from $2.800 billion-$3.000 billion to $3.100 billion-$3.300 billion vs $2.928 billion estimate.
EARNINGS | Aug 10, 2026, 08:10 PM UTC
L
HIMS Raises FY26 Sales Guidance To $3.1B-$3.3B; Sees Adj. EBITDA $275M-$325M
HIMS Raises FY26 Sales Guidance To $3.1B-$3.3B; Sees Adj. EBITDA $275M-$325M
EARNINGS | Aug 10, 2026, 08:07 PM UTC
L
Hims & Hers Stock Missed Estimates Last Quarter — Can It Turn the Page Tonight?
Hims & Hers Health Inc. (NYSE: HIMS ) shares are in the spotlight Monday ahead of the company’s second-quarter earnings report today after the market closes. Hims & Hers Health shares are under pressure. Why is HIMS stoc
EARNINGS | Aug 10, 2026, 01:48 PM UTC
H
HIMS jumps 10%
HIMS stock price increases 10%
EQUITY | Aug 03, 2026, 03:43 PM UTC
H
Hims & Hers Responds to FTC Lawsuit
Hims & Hers defends against FTC lawsuit
REGULATION | Jul 29, 2026, 05:53 PM UTC
L
HIMS Issues Correction
HIMS issues correction statement
EQUITY | Jul 29, 2026, 05:45 PM UTC
L
HIMS says on FTC lawsuit: we are confident in our position and will vigorously defend ourselves against these baseless claims
HIMS says on FTC lawsuit: we are confident in our position and will vigorously defend ourselves against these baseless claims
REGULATION | Jul 29, 2026, 05:17 PM UTC
L
HIMS says on FTC lawsuit: lawsuit disregards substantial evidence we provided the FTC during its nearly three-year investigation
HIMS says on FTC lawsuit: lawsuit disregards substantial evidence we provided the FTC during its nearly three-year investigation
REGULATION | Jul 29, 2026, 05:17 PM UTC
L
HIMS has extended declined -12.5% on FTC headlines
HIMS has extended declined -12.5% on FTC headlines
REGULATION | Jul 29, 2026, 04:58 PM UTC
L
HIMS Continues Down
HIMS stock price continues to decline
EQUITY | Jul 29, 2026, 04:51 PM UTC
H
HIMS Down on Volume
HIMS trading lower on high volume
EQUITY | Jul 29, 2026, 04:30 PM UTC
L
HIMS lows -9% The U.S. Federal Trade Commission is suing Hims & Hers (HIMS) alleging the Telehealth platform shared users' health data with
HIMS lows -9% The U.S. Federal Trade Commission is suing Hims & Hers (HIMS) alleging the Telehealth platform shared users' health data with online advertisers despite promising privacy and engaged in deceptive billing an
REGULATION | Jul 29, 2026, 04:30 PM UTC
H
Jim Cramer: Arista Is ‘Terrific,’ Also Likes This Consumer Cyclical Stock
On CNBC’s “ Mad Money Lightning Round,” Jim Cramer said he likes Ross Stores, Inc. (NASDAQ: ROST ). On the earnings front, Ross Stores, on May 21, reported better-than-expected first-quarter financial results and raised
EARNINGS | Jul 29, 2026, 12:12 PM UTC
L
Hims & Hers down as FDA advisors snub first peptide
Hims & Hers down as FDA advisors snub first peptide
EQUITY | Jul 24, 2026, 05:02 PM UTC
L
HIMS giving back all its Thursday gains after FDA peptide news, down -10%
HIMS giving back all its Thursday gains after FDA peptide news, down -10%
REGULATION | Jul 24, 2026, 03:22 PM UTC
L
HIMS Reiterate Buy, $40 PT after FDA peptide vote today @ Canaccord
HIMS Reiterate Buy, $40 PT after FDA peptide vote today @ Canaccord
REGULATION | Jul 23, 2026, 08:29 PM UTC
L
HIMS still going on FDA peptide headlines at highs +12.8% at $35.75
HIMS still going on FDA peptide headlines at highs +12.8% at $35.75
REGULATION | Jul 23, 2026, 05:21 PM UTC
L
Hims & Hers rises after FDA advisers endorse broader BPC-157 access
Shares of Hims & Hers...
REGULATION | Jul 23, 2026, 05:09 PM UTC
L
HIMS popping to highs +8.9% after FDA news
HIMS popping to highs +8.9% after FDA news
REGULATION | Jul 23, 2026, 04:47 PM UTC
L
HIMS FDA advisory panel votes to place bpc-157 peptide on allowed pharmacy compounding list
HIMS FDA advisory panel votes to place bpc-157 peptide on allowed pharmacy compounding list
REGULATION | Jul 23, 2026, 04:40 PM UTC
L
HIMS highs +2.4%
HIMS highs +2.4%
EQUITY | Jul 23, 2026, 02:08 PM UTC
L
AKTS PBLS HIMS Today and tomorrow, an FDA advisory committee will mull whether compounding pharmacies should be allowed to manufacture seven
AKTS PBLS HIMS Today and tomorrow, an FDA advisory committee will mull whether compounding pharmacies should be allowed to manufacture seven peptides, in particular. This could mean a clash between career FDA scientists,
REGULATION | Jul 23, 2026, 12:13 PM UTC
L
HIMS +3% as U.S. FDA advisers this week will weigh whether seven Popular peptides can be compounded by licensed pharmacies
HIMS +3% as U.S. FDA advisers this week will weigh whether seven Popular peptides can be compounded by licensed pharmacies
REGULATION | Jul 22, 2026, 01:37 PM UTC
L
AKTS PBLS HIMS U.S. FDA advisers this week will weigh whether seven Popular peptides can be compounded by licensed pharmacies, but even if r
AKTS PBLS HIMS U.S. FDA advisers this week will weigh whether seven Popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry participants say consumer demand is
REGULATION | Jul 22, 2026, 11:08 AM UTC
L
HIMS hims & hers chief accounting officer, irene becklund, announces departure from the company
HIMS hims & hers chief accounting officer, irene becklund, announces departure from the company
EQUITY | Jul 17, 2026, 08:17 PM UTC
L
HIMS a late afternoon pop, at highs rising 6.4% to $37.40
HIMS a late afternoon pop, at highs rising 6.4% to $37.40
EQUITY | Jul 15, 2026, 06:34 PM UTC
L
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Investors to Learn More
NEW YORK CITY, NY / / July 5, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on
EQUITY | Jul 05, 2026, 03:00 PM UTC
L
Here’s How Much You Would Have Made Owning Hims & Hers Health Stock In The Last 5 Years
Hims & Hers Health (NYSE: HIMS ) has outperformed the market over the past 5 years by 17.4% on an annualized basis producing an average annual return of 28.89%. Currently, Hims & Hers Health has a market capitalization o
EQUITY | Jul 01, 2026, 09:30 PM UTC
H
Hims & Hers Stock Surges as Analysts Lift Price Targets
Hims & Hers Health Inc (NYSE: HIMS ) shares are rising on Wednesday after BofA Securities and Canaccord Genuity raised their respective price targets on the stock. Hims & Hers Health stock is charging ahead with explosiv
RATES | Jul 01, 2026, 06:49 PM UTC
L
Hims & Hers Health’s Peptide Opportunity Tempered By FDA Recommendation, Says Analyst
The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc ‘s (NYSE: HIMS ) peptide optionality narrative, BofA Securities said. Analyst Allen Lutz maintained a Neutral
REGULATION | Jul 01, 2026, 04:48 PM UTC
L
Hims & Hers Health shares are trading higher after B of A Securities and Canaccord Genuity raised their respective price targets on the stoc
Hims & Hers Health shares are trading higher after B of A Securities and Canaccord Genuity raised their respective price targets on the stock.
EQUITY | Jul 01, 2026, 02:48 PM UTC
L
Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $40
Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE: HIMS ) with a Buy and raises the price target from $32 to $40.
EQUITY | Jul 01, 2026, 01:34 PM UTC
L
B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $36
B of A Securities analyst Allen Lutz maintains Hims & Hers Health (NYSE: HIMS ) with a Neutral and raises the price target from $25 to $36.
EQUITY | Jul 01, 2026, 12:42 PM UTC
M
HIMS Returns 225%
A $100 investment in Hims & Hers Health 5 years ago would be worth $320.47 today
EARNINGS | Jun 23, 2026, 04:42 PM UTC
M
CVS Expands GLP-1 Offerings
CVS Pharmacy announces new GLP-1 offerings, including expanded pharmacy support and a new $49 MinuteClinic virtual visit
EQUITY | Jun 22, 2026, 12:10 PM UTC